Business Context and Reporting Period
Company: Akebia Therapeutics, Inc. (AKBA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2020
Subject: Favorable ruling on invalidity proceedings against FibroGen, Inc. in the United Kingdom regarding patents related to the Phase 3 product candidate vadadustat.
Key Financial Metrics
This filing is a current report regarding a legal event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Legal Proceedings
The Patents Court of the United Kingdom issued a judgment on April 20, 2020, in favor of Akebia and its collaboration partner, Otsuka Pharmaceutical Co. Ltd. The court invalidated all claims at issue in five of the six challenged FibroGen patents:
- European Patent (UK) No. 1463823 ('823 EP Patent)
- European Patent (UK) No. 1633333 ('333 EP Patent)
- European Patent (UK) No. 2322153 ('153 EP Patent)
- European Patent (UK) No. 2322155 ('155 EP Patent)
- European Patent (UK) No. 2298301 ('301 EP Patent)
Regarding the sixth patent, European Patent (UK) No. 2289531 ('531 EP Patent), the court held the single amended claim to be valid but determined it was not infringed by vadadustat. A seventh patent ('472 EP Patent) was previously dismissed from the lawsuit by agreement.
Outlook, Risks, and Management Commentary
The favorable ruling removes potential patent barriers for vadadustat in the United Kingdom. The filing does not provide specific forward-looking guidance, updated financial outlook, or new risk factors beyond the resolution of this specific litigation.
Investor Verification Checklist
- Confirm the specific scope of the invalidated patents and their impact on vadadustat commercialization in the UK.
- Verify the status of the '531 EP Patent claim regarding non-infringement and potential for future appeals.
- Review the collaboration agreement terms with Otsuka Pharmaceutical to understand royalty or milestone implications of this ruling.
- Check for any pending litigation in other jurisdictions (e.g., US, EU) involving the same patents.